<p>随着全球市场调整美联储最近的降息和混合经济信号，小型股表现出韧性，特别是在美国，罗素 2000 指数的表现优于大型同行。在这个动态环境中，识别亚洲有前景的股票需要敏锐的眼光，寻找能够应对货币政策变化并利用区域增长机会的公司。</p>
<h3>亚洲十大未被发现的基本面强劲的宝藏股</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>安徽华仁健康药业</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>华思控股</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>泰信电气</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>江西江南新材料科技</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>四川自贡输送机械集团</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>浙江博发电气</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲未被发现的基本面强劲的宝藏股筛选器中的 2502 只股票的完整列表。</p>
<p>在这里，我们重点介绍了我们独家的筛选器中的几只最爱。</p>
<h2>苏美达 (SHSE:600710)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 苏美达有限公司在中国从事供应和工业链业务，市值为 140.6 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过其在中国的供应和工业链业务产生收入，市值为 140.6 亿人民币。</p>
<p>苏美达过去一年的盈利增长为 9.8%，超过了贸易分销行业的-12.9% 的变化，突显了其在挑战性行业中的强劲表现。该公司报告 2025 年前九个月的净收入为 11.0369 亿人民币，较去年 1,003.08 亿人民币有所增长。以显著折扣交易——比估计的公允价值低 67.1%——苏美达似乎相较于同行和行业标准被低估。值得注意的是，其负债权益比在五年内从 81.3% 显著改善至仅 22.6%，这表明其财务管理有效，未来增长潜力巨大。</p>
<ul>
<li>点击这里深入了解苏美达的完整分析健康报告。</li>
<li>通过查看我们的历史业绩报告，获取苏美达的历史表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600710 截至 2025 年 12 月的盈利和收入增长</p>
<h2>天水中兴生物科技有限公司 (SZSE:002772)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 天水中兴生物科技有限公司从事食用真菌的研究、开发、生产和销售，业务覆盖中国及国际市场，市值约为 53.6 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要从农业种植行业产生收入，报告收入约为 19.9 亿人民币。</p>
<p>天水中兴生物科技在生物科技领域是一家有前景的参与者，过去一年其盈利增长达到 235%，超过了食品行业 4.8% 的整体增长。该公司 2025 年前九个月的净收入达到 2.04 亿人民币，显著高于去年 8900 万人民币。以 22 倍的市盈率相比中国市场平均 42.9 倍仍具吸引力。其债务管理值得称赞，负债权益比在五年内从 91.8% 降至 74.1%，利息覆盖率接近十六倍 EBIT。</p>
<ul>
<li>点击探索我们在天水中兴生物科技有限公司健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取天水中兴生物科技有限公司的过去表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002772 截至 2025 年 12 月的负债权益比</p>
<h2>久光制药 (TSE:4530)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 久光制药株式会社专注于在日本制造和销售药品，市值为 3046.3 亿日元。</p>
<p><strong>运营：</strong> 该公司主要通过在日本销售药品产生收入。其财务表现受生产成本和市场需求等因素的影响。市值为 3046.3 亿日元，反映了其在行业中的地位。</p>
<p>在制药行业具有显著影响力的久光制药，过去一年显示出 34% 的强劲盈利增长，超过行业平均 9.6%。以显著折扣交易，低于其估计公允价值的 53.5%。该公司财务状况良好，现金超过总债务，且自由现金流为正。最近的战略举措包括完成价值 122.7 亿日元的股票回购计划，提升了股东价值。此外，他们将股息从每股 43 日元提高至 45 日元，反映了对其财务健康和未来前景的信心。</p>
<ul>
<li>点击这里发现久光制药的细微差别，查看我们的详细分析健康报告。</li>
<li>通过我们的历史报告获取久光制药的过去趋势和表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4530 截至 2025 年 12 月的盈利和收入增长</p>
<h2>接下来该如何？</h2>
<ul>
<li>在这里深入了解我们完整的 2502 个具有强大基本面的亚洲未被发现的宝藏。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用程序。</li>
</ul>
<h2>考虑其他策略？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾害</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

苏美达

<p>这篇文章强调了在全球市场调整中，亚洲有前景的小型股票。它列出了 10 家基本面强劲的公司，包括苏美达、天水中兴生物科技和久光制药。苏美达显示出强劲的盈利增长和改善的债务管理。天水中兴生物科技具有显著的盈利增长和吸引人的估值。久光制药展现出强劲的盈利增长、良好的财务健康和股东价值提升。文章鼓励探索完整的 2502 只股票名单，并使用 Simply Wall St 获取投资见解</p>

<p>As global markets adjust to the Federal Reserve's recent interest rate cut and mixed economic signals, small-cap stocks have shown resilience, particularly in the U.S., with the Russell 2000 Index outperforming its larger peers. In this dynamic environment, identifying promising stocks in Asia requires a keen eye for companies that can navigate shifting monetary policies and capitalize on regional growth opportunities.</p>
<div class="lb-trans"><p>随着全球市场调整美联储最近的降息和混合经济信号，小型股表现出韧性，特别是在美国，罗素 2000 指数的表现优于大型同行。在这个动态环境中，识别亚洲有前景的股票需要敏锐的眼光，寻找能够应对货币政策变化并利用区域增长机会的公司。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In Asia</h3>
<div class="lb-trans"><h3>亚洲十大未被发现的基本面强劲的宝藏股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Anhui Huaren Health Pharmaceutical</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Huasi Holding</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Tai Sin Electric</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Jiangxi Jiangnan New Material Technology</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Sichuan Zigong Conveying Machine Group</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Zhejiang Bofay Electric</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>安徽华仁健康药业</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>华思控股</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>泰信电气</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>江西江南新材料科技</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>四川自贡输送机械集团</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>浙江博发电气</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 2502 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲未被发现的基本面强劲的宝藏股筛选器中的 2502 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在这里，我们重点介绍了我们独家的筛选器中的几只最爱。</p>
</div><h2>Sumec (SHSE:600710)</h2>
<div class="lb-trans"><h2>苏美达 (SHSE:600710)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Sumec Corporation Limited operates in the supply and industrial chain business in China, with a market cap of CN¥14.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 苏美达有限公司在中国从事供应和工业链业务，市值为 140.6 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily through its supply and industrial chain operations in China. It has a market capitalization of CN¥14.06 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其在中国的供应和工业链业务产生收入，市值为 140.6 亿人民币。</p>
</div><p>Sumec's earnings growth of 9.8% over the past year outpaced the Trade Distributors industry, which saw a -12.9% change, highlighting its robust performance in a challenging sector. The company reported net income of CNY 1,103.69 million for the first nine months of 2025, up from CNY 1,003.08 million last year. Trading at a significant discount—67.1% below estimated fair value—Sumec seems undervalued compared to peers and industry standards. Notably, its debt-to-equity ratio has improved dramatically from 81.3% to just 22.6% over five years, suggesting effective financial management and potential for future growth.</p>
<div class="lb-trans"><p>苏美达过去一年的盈利增长为 9.8%，超过了贸易分销行业的-12.9% 的变化，突显了其在挑战性行业中的强劲表现。该公司报告 2025 年前九个月的净收入为 11.0369 亿人民币，较去年 1,003.08 亿人民币有所增长。以显著折扣交易——比估计的公允价值低 67.1%——苏美达似乎相较于同行和行业标准被低估。值得注意的是，其负债权益比在五年内从 81.3% 显著改善至仅 22.6%，这表明其财务管理有效，未来增长潜力巨大。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Sumec.</li>
<li>Gain insights into Sumec's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解苏美达的完整分析健康报告。</li>
<li>通过查看我们的历史业绩报告，获取苏美达的历史表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600710 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:600710 截至 2025 年 12 月的盈利和收入增长</p>
</div><h2>Tianshui Zhongxing Bio-technologyLtd (SZSE:002772)</h2>
<div class="lb-trans"><h2>天水中兴生物科技有限公司 (SZSE:002772)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Tianshui Zhongxing Bio-technology Co., Ltd. is involved in the research, development, production, and sale of edible fungi both in China and internationally, with a market capitalization of approximately CN¥5.36 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 天水中兴生物科技有限公司从事食用真菌的研究、开发、生产和销售，业务覆盖中国及国际市场，市值约为 53.6 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily from the agricultural planting industry, with reported revenues of approximately CN¥1.99 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要从农业种植行业产生收入，报告收入约为 19.9 亿人民币。</p>
</div><p>Tianshui Zhongxing Bio-technology, a promising player in the biotech sector, has seen its earnings soar by 235% over the past year, outpacing the broader food industry growth of 4.8%. The company's net income for the first nine months of 2025 reached CNY 204 million, significantly up from CNY 89 million a year prior. With a price-to-earnings ratio of 22x, it remains attractively valued compared to China's market average of 42.9x. Its debt management is commendable with a reduced debt to equity ratio from 91.8% to 74.1% over five years and an interest coverage of nearly sixteen times EBIT.</p>
<div class="lb-trans"><p>天水中兴生物科技在生物科技领域是一家有前景的参与者，过去一年其盈利增长达到 235%，超过了食品行业 4.8% 的整体增长。该公司 2025 年前九个月的净收入达到 2.04 亿人民币，显著高于去年 8900 万人民币。以 22 倍的市盈率相比中国市场平均 42.9 倍仍具吸引力。其债务管理值得称赞，负债权益比在五年内从 91.8% 降至 74.1%，利息覆盖率接近十六倍 EBIT。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Tianshui Zhongxing Bio-technologyLtd's health report.</li>
<li>Review our historical performance report to gain insights into Tianshui Zhongxing Bio-technologyLtd's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在天水中兴生物科技有限公司健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取天水中兴生物科技有限公司的过去表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002772 Debt to Equity as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:002772 截至 2025 年 12 月的负债权益比</p>
</div><h2>Hisamitsu Pharmaceutical (TSE:4530)</h2>
<div class="lb-trans"><h2>久光制药 (TSE:4530)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hisamitsu Pharmaceutical Co., Inc. focuses on the manufacturing and sale of pharmaceuticals in Japan, with a market cap of ¥304.63 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 久光制药株式会社专注于在日本制造和销售药品，市值为 3046.3 亿日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the sale of pharmaceuticals in Japan. Its financial performance is influenced by factors such as production costs and market demand for its products. The market cap stands at ¥304.63 billion, reflecting its position within the industry.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过在日本销售药品产生收入。其财务表现受生产成本和市场需求等因素的影响。市值为 3046.3 亿日元，反映了其在行业中的地位。</p>
</div><p>With a notable presence in the pharmaceutical sector, Hisamitsu Pharmaceutical has shown robust earnings growth of 34% over the past year, outpacing the industry average of 9.6%. Trading at a significant discount, it stands 53.5% below its estimated fair value. The company is financially sound with more cash than total debt and positive free cash flow. Recent strategic moves include completing a share buyback program worth ¥12.27 billion, enhancing shareholder value. Furthermore, they have increased dividends to ¥45 per share from ¥43 previously, reflecting confidence in their financial health and future prospects.</p>
<div class="lb-trans"><p>在制药行业具有显著影响力的久光制药，过去一年显示出 34% 的强劲盈利增长，超过行业平均 9.6%。以显著折扣交易，低于其估计公允价值的 53.5%。该公司财务状况良好，现金超过总债务，且自由现金流为正。最近的战略举措包括完成价值 122.7 亿日元的股票回购计划，提升了股东价值。此外，他们将股息从每股 43 日元提高至 45 日元，反映了对其财务健康和未来前景的信心。</p>
</div><ul>
<li>Click here to discover the nuances of Hisamitsu Pharmaceutical with our detailed analytical health report.</li>
<li>Gain insights into Hisamitsu Pharmaceutical's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现久光制药的细微差别，查看我们的详细分析健康报告。</li>
<li>通过我们的历史报告获取久光制药的过去趋势和表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4530 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:4530 截至 2025 年 12 月的盈利和收入增长</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该如何？</h2>
</div><ul>
<li>Delve into our full catalog of 2502 Asian Undiscovered Gems With Strong Fundamentals here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解我们完整的 2502 个具有强大基本面的亚洲未被发现的宝藏。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 提升您的投资组合，这是寻求全球市场覆盖的投资者的终极应用程序。</li>
</ul>
</div><h2>Contemplating Other Strategies?</h2>
<div class="lb-trans"><h2>考虑其他策略？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾害</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

亚洲未被发现的宝藏：2025 年 12 月的潜力股